Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
6,97429472558288
Market Cap Growth
4719.92%309.03%31.21%-33.05%-7.27%-41.77%
Enterprise Value
6,55610841.0423.327.2660.36
Last Close Price
221.3826.8815.8815.1325.4040.00
PE Ratio
--1.00-3.02-1.57-1.57-1.11
PS Ratio
-230.783.090.851.657.32
PB Ratio
15.381.80-8.76-3.803.808.24
P/TBV Ratio
8.691.05-8.45-3.663.097.76
P/FCF Ratio
--1.67-3.14-1.92-3.24-1.62
P/OCF Ratio
--1.67-3.21-1.93-3.25-1.62
EV/Sales Ratio
-84.701.760.360.555.00
EV/EBITDA Ratio
--0.61-1.52-0.79-0.65-0.84
EV/EBIT Ratio
--0.61-1.52-0.78-0.65-0.84
EV/FCF Ratio
--0.61-1.79-0.82-1.08-1.11
Debt / Equity Ratio
0.000.02-0.59-0.080.230.74
Debt / EBITDA Ratio
-0.01-0.02-0.18-0.04-0.12-0.11
Debt / FCF Ratio
-0.01-0.02-0.21-0.04-0.20-0.15
Asset Turnover
-0.010.411.050.730.19
Quick Ratio
4.403.860.740.931.911.22
Current Ratio
4.624.250.901.092.111.48
Return on Equity (ROE)
-63.10%-219.59%221.48%-835.29%-263.05%-297.06%
Return on Assets (ROA)
-53.30%-124.97%-47.29%-48.84%-62.25%-111.05%
Return on Invested Capital (ROIC)
2102.77%1076.68%263.00%520.15%-1196.69%-851.80%
Return on Capital Employed (ROCE)
-66.48%-213.65%-949.64%-125.41%-133.79%-236.98%
Earnings Yield
-2.65%-99.52%-33.06%-63.52%-63.78%-90.00%
FCF Yield
-1.91%-60.04%-31.88%-52.15%-30.86%-61.83%
Buyback Yield / Dilution
-0.10%-114.64%-36.12%-4.31%-59.89%-45.57%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q